Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Q: Paragraph: A panel of Food and Drug Administration advisers voted unanimously in favor of Amgen's version of AbbVie's Humira, a biotech drug that raked in nearly $15 billion last year, according to IMS Health. While not binding, the recommendation likely paves the way for FDA approval of the knockoff drug. For years, biotech drugs faced no competition because there was no regulatory way to approve copycat versions, even after patents had expired. If approved, Amgen's drug would join a new wave of so-called biosimilars, which have the potential to generate billions in savings for U.S. insurers, doctors and patients. But it could take years for those savings to arrive. Evercore ISI analyst Mark Schoenebaum says the earliest Amgen could launch its product would be March 2017, though that would risk infringing patents which Abbvie says protect its drug until at least 2022. Wall Street analysts expect the patent issue to be fought in court, and then for Amgen's drug to launch sometime between 2018 and 2022. First approved in 2002, Humira has long been among the most profitable drugs in the world. It accounted for 60 percent of Abbvie's total revenue last year. The injectable drug, which blocks chemicals linked to inflammation, is approved for multiple uses, including rheumatoid arthritis, Crohn's disease and psoriasis. Thousand Oaks, Calif-based Amgen is seeking FDA approval to market its version, known only as ABP 501, for seven diseases. Amgen is itself a biotech powerhouse, and it too has medications facing competition from cheaper versions. The company is working to hedge those loses by developing lower-cost versions of competitors' drugs. Biotech drugs are powerful, injected medicines produced in living cells that are typically much more expensive than traditional, chemical-based drugs. In 2015, six of the 10 top-selling medicines globally were biotech drugs, with more than $56 billion in combined sales. The FDA only approved the first lower-cost biotech drug last March, a Novartis version of the Amgen drug Neupogen. Pfizer won approval to market a second biosimilar in April, a version of Johnson & Johnson's Remicade, but it is not yet for sale. Questions remain about just how much savings U.S. biosimilars will deliver. Novartis' Zarxio sells for 15 percent less than the original Neupogen. Experts predict biosimilar discounts of 15 percent to 30 percent in the U.S. In Europe, where governments regulate prices, discounts are higher. Development of lower-cost anti-inflammatory drugs like Humira is considered pivotal in reducing U.S. spending on specialty drugs, which has doubled to $150 billion since 2010, according to IMS Health. On Wednesday, the same panel of FDA advisers will review a Novartis version of Enbrel, which is marketed by Amgen. Claim: Lower-cost biotech drug gets thumbs up from FDA panel.

A: The second-biggest selling drug in the world could get some cheaper competition in the U.S., after a federal panel endorsed an alternative version of the pricey medication used to treat rheumatoid arthritis and other inflammatory diseases.
****
Q: Paragraph: There will be 50,000 more nurses going into the NHS. The government has committed to do this by 2024/25. Not all of these nurses will be 'new'. The government have announced the end of hospital parking charges for patients. In December it was announced that hospitals in England will have to provide free car parking to frequent hospital visitors, blue badge holders and at certain times to staff and parents of child patients. The government will build 40 new hospitals. Six hospitals in England are getting the money to upgrade their buildings within the next five years. Up to 38 hospitals are getting money to develop plans for their hospitals between 2025 and 2030, but not to actually begin any building work. The government is putting 20,000 more police on the streets. The government has committed to do this. If this happens it will take the number of police in England and Wales to almost, but not quite the same level as it was at in 2010. The government gave the police much more use of Tasers to help deal with street crime. The Home Office announced police in England and Wales can bid for part of a fund to equip their force with more Tasers. Final funding allocations will be announced in February. The government are lifting the living wage by the biggest ever amount, up to 8.72, and it will go up to 10.50. The national living wage set by the government is set to rise to 8.72 in April, the largest rise since it was put in place in 2016. It was also announced at last year's Conservative party conference that it would rise to 10.50 within the next five years. Claim 1 of 7 Claim: The government are lifting the living wage by the biggest ever amount, up to 8.72, and it will go up to 10.50.

A: The national living wage set by the government is set to rise to 8.72 in April, the largest rise since it was put in place in 2016. It was also announced at last year's Conservative party conference that it would rise to 10.50 within the next five years.
****
Q: Paragraph: Despite a 25-year-old international ban on most international elephant ivory trade, poachers are illegally slaughtering elephants by the thousands for their tusks and wildlife advocates blame the remaining ivory trade. In the United States, regulations against trading in ivory are tightening. The state of New York has adopted a near total ban and the Obama administration is tightening federal rules. This is unfair, say people like Defrin, whose gallery sells costly figurines, vases and other ivory curios. Such antiques contain ivory taken from elephants in the distant past, sometimes centuries ago, and should not be subject to sales restrictions, they say. Defrin said regulations already in place have damaged his business, drying up European demand for his goods and restricting import of ivory. "They've basically ruined the collective antique trade," he said. "Is this really something that will stop poor African people from killing elephants?" Yes, say wildlife advocates and regulators. They say an "antique loophole" in existing rules sometimes allows new ivory to be disguised as old, fueling global demand for tusks and keeping illegal poaching profitable. "This poaching crisis in Africa is being driven by demand for ivory," said Laura Noguchi, a biologist with the U.S. Fish and Wildlife Service. With the U.S. Congress back this month after a summer break, a fight over ivory trade regulation is taking shape. It will not be a top priority for lawmakers faced with other urgent decisions. But it may get attention due to the involvement of the National Rifle Association. One of Washington's most powerful special interest groups, the NRA is advocating for the interests of gun enthusiasts with ivory-decorated weapons. Alaska's Don Young and California's Ken Calvert, both Republican representatives, are offering legislation to soften Obama administration restrictions issued over the last year. "The administration's ivory rule is well-intentioned, but was not crafted carefully enough to account for law-abiding Americans who may possess legally obtained products containing ivory," Calvert told Reuters in a statement. Ivory has been used for hundreds of years in manufacturing items such as the tips of bows for stringed instruments, piano keys, decorative items for the home, and importantly, for ornamental inlays in rifle and shotgun stocks and handgun grips. Even though the ivory trade is largely curbed globally under the Convention on International Trade in Endangered Species of Wild Fauna and Flora (CITES), an estimated 100,000 African elephants were killed by poachers between 2010 and 2012, according to a study last year by the National Academy of Sciences. Much of the demand for ivory comes from Asia. In China, a growing affluent class has increasingly sought ivory as an ornamental item. Some experts have reported that speculators in eastern Asia are stockpiling raw ivory, hoping it will fetch higher prices in the future. The U.S. Fish and Wildlife Service, which regulates ivory sales on a federal level, said the United States is a "significant market" for ivory, though it had no detailed estimates for ivory trading in the country. The agency issued a director's order last year prohibiting commercial import of all ivory, without exception, and clarified other limits on ivory exports. The agency followed up that order with a proposal in July that would further limit exports of ivory to legally qualified antiques. The proposal would offer an exemption allowing the sale of certain manufactured items that contain less than 200 grams (7 ounces) of ivory, a move the service said should include most firearms and musical instruments. New York state outlawed the sale of ivory last year, offering exceptions only for items proven to be antique and containing only a small amount of ivory. Earlier this month, California's legislature approved a similar measure. Just how much new illegal ivory may be "laundered" as antique is unclear. A study of ivory for sale in Los Angeles in 2014 commissioned by the Natural Resources Defense Council, an environmental group, found that up to 90 percent of the ivory surveyed may have been illegal under California law, and as much as 60 percent may have been prohibited under federal law. The study's author, Daniel Stiles, cautioned that determining the age of ivory by visual examination is subjective. The only way to firmly date ivory is based on carbon dating and DNA tests, which are costly and require cutting into the ivory. Wildlife groups have applauded the Obama administration's actions and are seeking more bans at the state level on even the sale of antique ivory similar to New York's statute. "The more we can eliminate legal markets in ivory, the more difficult it becomes to sell ivory illegally," said Andrew Wetzler, director of the wildlife program for the Natural Resources Defense Council. Claim: Push to save African elephants stirs U.S. clash over antique ivory trade.

A:
The ornate ivory statues and carvings sold in Scott Defrin's New York gallery date from the 17th and 18th centuries, but the antique dealer's business is being upended by a 21st century fight over saving the African elephant.
****